Obseva Sa Stock News

ObsEva SA. (OBSV) shares closed today at 1.6% above its 52 week low of $1.91, giving the company a market cap of $165M. The stock is currently down 2.5% year-to-date, down 6.7% over the past 12 months, and down 83.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 340.0% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 864.1% The company's stock price performance over the past 12 months beats the peer average by -23.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

ObsEva SA. (OBSV) shares closed today at 1.5% above its 52 week low of $1.97, giving the company a market cap of $175M. The stock is currently up 3.5% year-to-date, down 5.5% over the past 12 months, and down 82.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 42.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 391.1% The company's stock price performance over the past 12 months beats the peer average by -28.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Futures Steady After Fed-Inspired Rout As Tech, Bitcoin Slide Continues US equity futures were little changed after earlier swings as traders digested hawkish Fed minutes that sparked a global stock rout on Wednesday. As discussed yesterday, minutes from the Feds December meeting showed a growing preference for a faster path of rate hikes and a shrinking of the banks balance sheet (one which would lead to yet another market crash and even more stimulus). However, while rising rates is terrible news for tech and high duration names, it''s good news for the value sector, and investors bet while the Fed''s faster-than-expected policy tightening (which will lead to faster than expected easing) may crimp highly valued technology stocks it will offer opportunities in other equity sectors, and sure enough with Nasdaq futures bombing again, energy names like Exxon are at 2 year highs. Treasury yields extended a spike, with the 10Y rising to 1.75%, the dollar was unchanged and bitcoin''s plunge continued even though the selling in stocks has subsided.

ObsEva (OBSV) perks up 6.3% premarket after announcing positive topline results from Phase 3 EDELWEISS 3 trial of linzagolix, an oral GnRH antagonist, in women with

-Once daily linzagolix 200 mg with ABT met both co-primary efficacy objectives, demonstrating reductions in dysmenorrhea and non-menstrual pelvic pain versus placebo at 3 months; showed statistically significant and clinically meaningful improvements versus placebo in ranked secondary endpoints of dysmenorrhea, non-menstrual pelvic pain, dyschezia, overall pelvic pain, and ability to perform daily activities at 6 months-

GENEVA, Switzerland January 3 , 202 2 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today

Penny stocks under $3 are full of potential and potential pitfalls. These are relatively safe and worth your consideration.

GENEVA, Switzerland December 20, 2021 - ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women''s reproductive health, today…

GENEVA, Switzerland December 20 , 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective as of market open on Monday, December 20, 2021.

ObsEva SA (NASDAQ:OBSV) was the target of a large growth in short interest in the month of November. As of November 30th, there was short interest totalling 3,240,000 shares, a growth of 40.9% from the November 15th total of 2,300,000 shares. Approximately 5.4% of the companys stock are short sold. Based on an average daily []

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval for ObsEva SA''s (NASDAQ: OBSV ) linzagolix, an oral GnRH antagonist to manage moderate to severe symptoms of uterine fibroids. If approved, linzagolix would be the first and only approved GnRH receptor antagonist with a non-hormonal Full story available on Benzinga.com

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval for ObsEva SA's (NASDAQ: OBSV) linzagolix, an oral

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland - December 13, 2021 - ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and comm

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange